Tags

Type your tag names separated by a space and hit enter

Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020.
Clin Infect Dis. 2020 07 28; 71(15):825-832.CI

Abstract

BACKGROUND

On 7 February 2020, French Health authorities were informed of a confirmed case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an Englishman infected in Singapore who had recently stayed in a chalet in the French Alps. We conducted an investigation to identify secondary cases and interrupt transmission.

METHODS

We defined as a confirmed case a person linked to the chalet with a positive reverse-transcription polymerase chain reaction sample for SARS-CoV-2.

RESULTS

The index case stayed 4 days in the chalet with 10 English tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in England (including the index case), and 1 in Spain (overall attack rate in the chalet: 75%). One pediatric case, with picornavirus and influenza A coinfection, visited 3 different schools while symptomatic. One case was asymptomatic, with similar viral load as that of a symptomatic case. Seven days after the first cases were diagnosed, 1 tertiary case was detected in a symptomatic patient with from the chalet a positive endotracheal aspirate; all previous and concurrent nasopharyngeal specimens were negative. Additionally, 172 contacts were monitored; all contacts tested for SARS-CoV-2 (N = 73) were negative.

CONCLUSIONS

The occurrence in this cluster of 1 asymptomatic case with similar viral load as a symptomatic patient suggests transmission potential of asymptomatic individuals. The fact that an infected child did not transmit the disease despite close interactions within schools suggests potential different transmission dynamics in children. Finally, the dissociation between upper and lower respiratory tract results underscores the need for close monitoring of the clinical evolution of suspected cases of coronavirus disease 2019.

Authors+Show Affiliations

French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.Infectious Diseases Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France. Fédération d'infectiologie multidisciplinaire de l'Arc Alpin, Université Grenoble Alpes, Grenoble, France. Unité Mixte de Recherche 5075 (UMR 5075), Institut de biologie structurale, Grenoble, France.French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.Department of Virology, Infective Agents Institute, National Reference Center for Respiratory Viruses North Hospital Network, Lyon, France.Regional Health Agency of Auvergne Rhône Alpes, Lyon, France.Infectious Diseases Department, University Hospital of Saint-Etienne, Lyon, France. Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, St-Etienne, France.Department of Virology, Infective Agents Institute, National Reference Center for Respiratory Viruses North Hospital Network, Lyon, France.French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.Infectious and Tropical Disease Department, Croix-Rousse Hospital, University Hospital of Lyon, Lyon, France.French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.Regional Health Agency of Auvergne Rhône Alpes, Lyon, France.Infectious Diseases Unit, Centre Hospitalier Annecy Genevois, Annecy, France.Regional Health Agency of Auvergne Rhône Alpes, Lyon, France.French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.Infectious Disease Department, Centre Hospitalier Metropole Savoie, Chambery, France.Service d'Hygiène Hospitalière et de Gestion des Risques, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France. Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques, Applications, Grenoble, Unité Mixte de Recherche 5525 (TIMC-IMAG UMR5525), CNRS, Université Grenoble Alpes, Grenoble, France.French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.Infectious Diseases Department, University Hospital of Saint-Etienne, Lyon, France. Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, St-Etienne, France.Public Health Emergency Operations Center, French Ministry of Health, Paris, France.French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.Infectious and Tropical Disease Department, Croix-Rousse Hospital, University Hospital of Lyon, Lyon, France. Maladies Infectieuses et Tropicales, Université Claude Bernard Lyon 1 (UCBL1), Unité de formation et de recherche (UFR) Lyon Sud-Charles Mérieux, Lyon, France.Department of Virology, Infective Agents Institute, National Reference Center for Respiratory Viruses North Hospital Network, Lyon, France.French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32277759

Citation

Danis, Kostas, et al. "Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 71, no. 15, 2020, pp. 825-832.
Danis K, Epaulard O, Bénet T, et al. Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. Clin Infect Dis. 2020;71(15):825-832.
Danis, K., Epaulard, O., Bénet, T., Gaymard, A., Campoy, S., Botelho-Nevers, E., Bouscambert-Duchamp, M., Spaccaferri, G., Ader, F., Mailles, A., Boudalaa, Z., Tolsma, V., Berra, J., Vaux, S., Forestier, E., Landelle, C., Fougere, E., Thabuis, A., Berthelot, P., ... Saura, C. (2020). Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 71(15), 825-832. https://doi.org/10.1093/cid/ciaa424
Danis K, et al. Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. Clin Infect Dis. 2020 07 28;71(15):825-832. PubMed PMID: 32277759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. AU - Danis,Kostas, AU - Epaulard,Olivier, AU - Bénet,Thomas, AU - Gaymard,Alexandre, AU - Campoy,Séphora, AU - Botelho-Nevers,Elisabeth, AU - Bouscambert-Duchamp,Maude, AU - Spaccaferri,Guillaume, AU - Ader,Florence, AU - Mailles,Alexandra, AU - Boudalaa,Zoubida, AU - Tolsma,Violaine, AU - Berra,Julien, AU - Vaux,Sophie, AU - Forestier,Emmanuel, AU - Landelle,Caroline, AU - Fougere,Erica, AU - Thabuis,Alexandra, AU - Berthelot,Philippe, AU - Veil,Raphael, AU - Levy-Bruhl,Daniel, AU - Chidiac,Christian, AU - Lina,Bruno, AU - Coignard,Bruno, AU - Saura,Christine, AU - ,, PY - 2020/03/05/received PY - 2020/04/09/accepted PY - 2020/4/12/pubmed PY - 2020/8/11/medline PY - 2020/4/12/entrez KW - COVID-19 KW - SARS-CoV-2 KW - cluster KW - coronavirus KW - infection SP - 825 EP - 832 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 71 IS - 15 N2 - BACKGROUND: On 7 February 2020, French Health authorities were informed of a confirmed case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an Englishman infected in Singapore who had recently stayed in a chalet in the French Alps. We conducted an investigation to identify secondary cases and interrupt transmission. METHODS: We defined as a confirmed case a person linked to the chalet with a positive reverse-transcription polymerase chain reaction sample for SARS-CoV-2. RESULTS: The index case stayed 4 days in the chalet with 10 English tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in England (including the index case), and 1 in Spain (overall attack rate in the chalet: 75%). One pediatric case, with picornavirus and influenza A coinfection, visited 3 different schools while symptomatic. One case was asymptomatic, with similar viral load as that of a symptomatic case. Seven days after the first cases were diagnosed, 1 tertiary case was detected in a symptomatic patient with from the chalet a positive endotracheal aspirate; all previous and concurrent nasopharyngeal specimens were negative. Additionally, 172 contacts were monitored; all contacts tested for SARS-CoV-2 (N = 73) were negative. CONCLUSIONS: The occurrence in this cluster of 1 asymptomatic case with similar viral load as a symptomatic patient suggests transmission potential of asymptomatic individuals. The fact that an infected child did not transmit the disease despite close interactions within schools suggests potential different transmission dynamics in children. Finally, the dissociation between upper and lower respiratory tract results underscores the need for close monitoring of the clinical evolution of suspected cases of coronavirus disease 2019. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/32277759/Cluster_of_Coronavirus_Disease_2019__COVID_19__in_the_French_Alps_February_2020_ DB - PRIME DP - Unbound Medicine ER -